Seagen Inc (SGEN)

[n4807g]

Dendreon recommended ahead of CMS decision at Canaccord

On Wednesday June 29, 2011, 7:12 am EDT

Canaccord recommends buying Dendreon ahead of the expected positive decision from CMS regarding Provenge reimbursement and the expected FDA approval on its new Orange County facility. Both decisions are expected by June 30. Shares are Buy rated with a $65 price target.

Bulls Eye!

http://finance.yahoo.com/news/Dendreon-recommended-ahead-theflyonthewall-1451936988.html?x=0&.v=1

Their recommendation and $1.09 will get a cup of coffee. Apparently they have entirely discounted the technology, or they want to buy shares.....